This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jul 28, 2025
•
7 min read
🧬 Hengrui & GSK link-up on 12 medicines, while Roche still in it for the gene therapy long-game
Jul 25, 2025
8 min read
🧬 3-peat of CGT layoffs, Eli Lilly goes in on molecular gates (up to $856M), and FDA (likely) wants new safety studies for Sarepta's Elevidys
Jul 24, 2025
🧬 Dispatch Bio's $200M+ launch against solid tumors, FDA opens up 1-2 month priority review pathway, and Sarepta-partner Arrowhead still confident on state of $550M licensing deal
Jul 23, 2025
🧬 Sanofi's $1.6B vaccine acquisition, while Replimmune's viral immunotherapy for melanoma lands an FDA rejection.
Jul 22, 2025
9 min read
🧬 Sarepta continues dominating headlines, while AstraZeneca and Biogen commit billions to US domestic manufacturing
Jul 21, 2025
🧬 Sarepta Therapeutics to square off with the FDA on Elevidys gene therapy, while Moderna cancelled mRNA factory in Japan
Jun 18, 2025
12 min read
A long form piece by yours truly - originally published on Signals
May 16, 2025
Some hard truths about TLDR Biotech
May 7, 2025
13 min read
Bristol Myers Squibb pledges $40B for US R&D and manufacturing, NewLimit $130M Series B with ambitions to develop epigenetic drugs to extend healthy lifespan using AI and genomics, Trump orders FDA to streamline drug factory regulations and reduce building timeframes from 5-10 years + 34 more stories
May 6, 2025
European Commission pledges €500M ($568M) in research funding to attract scientists amid US funding cuts, Deerfield Management raises $600M Healthcare Innovations Fund to invest in therapeutics and AI, Novo Nordisk's oral Wegovy (semaglutide) formulation awaits FDA approval decision by Q4, Bristol Myers Squibb cutting 516 more jobs in New Jersey + 31 more stories
May 5, 2025
11 min read
Aviva Capital Partners announces plans for £1B ($1.3B) cancer research and treatment hub in London, Kura Oncology earns $45M milestone payment from Kyowa Kirin for ziftomenib NDA submission in acute leukemias, Amgen executives advocate for tax incentives (not tariffs) to boost US pharmaceutical manufacturing, Pliant Therapeutics cuts 45% of workforce to extend cash ahead of results from halted idiopathic pulmonary fibrosis drug study + 26 more stories
May 4, 2025
Looking back on what's been an eventful year
